KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) EBT Margin (2017 - 2025)

Bionano Genomics (BNGO) has disclosed EBT Margin for 9 consecutive years, with 99.33% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 15256.0% to 99.33% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 92.36% through Dec 2025, up 27293.0% year-over-year, with the annual reading at 92.35% for FY2025, 27294.0% up from the prior year.
  • EBT Margin hit 99.33% in Q4 2025 for Bionano Genomics, up from 115.23% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 47.93% in Q1 2025 to a low of 1207.63% in Q3 2023.
  • Historically, EBT Margin has averaged 403.77% across 5 years, with a median of 442.59% in 2022.
  • Biggest five-year swings in EBT Margin: tumbled -76751bps in 2023 and later skyrocketed 61294bps in 2025.
  • Year by year, EBT Margin stood at 455.66% in 2021, then grew by 1bps to 448.84% in 2022, then rose by 9bps to 409.73% in 2023, then soared by 39bps to 251.89% in 2024, then skyrocketed by 61bps to 99.33% in 2025.
  • Business Quant data shows EBT Margin for BNGO at 99.33% in Q4 2025, 115.23% in Q3 2025, and 101.69% in Q2 2025.